<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>Old, Frail and on Costly Drugs</title>
    <meta content="LTR004537" name="slug"/>
    <meta content="13" name="publication_day_of_month"/>
    <meta content="7" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Thursday" name="publication_day_of_week"/>
    <meta content="Editorial Desk" name="dsk"/>
    <meta content="28" name="print_page_number"/>
    <meta content="A" name="print_section"/>
    <meta content="4" name="print_column"/>
    <meta content="Opinion" name="online_sections"/>
    <docdata>
      <doc-id id-string="1214614"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Medicine and Health</classifier>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Prices (Fares, Fees and Rates)</classifier>
        <person class="indexing_service">Rosenblatt, Roger A (Dr)</person>
        <classifier class="online_producer" type="types_of_material">Letter</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion/Letters</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion</classifier>
        <classifier class="online_producer" type="general_descriptor">Prices (Fares, Fees and Rates)</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000713T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9E0DE0DA1F38F930A25754C0A9669C8B63" item-length="212" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>Old, Frail and on Costly Drugs</hl1>
      </hedline>
      <abstract>
        <p>Dr Roger A Rosenblatt letter says July 9 article on escalating prices of prescription drugs glossed over medical profession's dependence on pharmaceutical company largess</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>To the Editor:</p>
        <p>Your July 9 Week in Review article about the escalating prices of  drugs glossed over one of the root causes of the problem: the illicit affair between the pharmaceutical industry and the medical profession.</p>
      </block>
      <block class="full_text">
        <p>To the Editor:</p>
        <p>Your July 9 Week in Review article about the escalating prices of  drugs glossed over one of the root causes of the problem: the illicit affair between the pharmaceutical industry and the medical profession.</p>
        <p>From the day a future doctor enters medical school, she is bombarded with gifts intended to create a sense of dependence on the drug companies. The doctor comes to depend on the unending flow of inducements: meals, conferences, trips, drug samples, free journals and even financial incentives for prescribing and promoting expensive new medicines.</p>
        <p>This unholy pas de deux leads to overprescription of costly drugs when cheaper alternatives would work as well. The entanglement serves the drug companies but undermines the integrity and independence of the medical profession.</p>
        <p>ROGER A. ROSENBLATT, M.D.  Seattle, July 10, 2000</p>
        <p>The writer is vice chairman, department of family medicine, University of Washington.</p>
      </block>
    </body.content>
  </body>
</nitf>
